ÁCIDO URSODESOXICÓILICO

CLAVE Y PRESENTACIÓN:

INDICACIONES:
Colestasis asociada a nutrición parenteral, atresia de vías biliares y fibrosis quística.

Buena absorción oral. Se conjuga con taurina o glicina y entra en la circulación enterohepática, se
hidroliza a ácido litocólico y se excreta en las heces.
Vida media sérica de 3 a 4 días en adultos.

Safe use has also been reported

in a patient with primary biliary cirrhosis who took the drug throughout pregnancy. Nothing is known about its use
during lactation, but it seems unlikely to cause a problem. Reports suggest that the drug is of benefit in some babies
with cholestasis due to biliary atresia, cystic fibrosis, and Alagille syndrome, although it is less clear whether it delays
the development of cirrhotic liver damage. Unfortunately, while it may reduce the serum bilirubin level in babies who
are developing cholestasis as a complication of prolonged parenteral nutrition, liver enzyme levels usually remain high.
Side effects are uncommon, although intestinal discomfort may occur when the drug is first introduced, and diarrhoea
has occasionally been reported.

Contraindicated in calcified cholesterol stones, radiopaque stones, bile pigment stones, or

stones > 20 mm in diameter. Use with caution in patients with nonvisualizing gallbladder
and chronic liver disease. May cause GI disturbance, rash, arthralgias, anxiety, headache,
and elevated liver enzymes.

Aluminum-containing antacids, cholestyramine, and oral contraceptives decrease ursodiol

effectiveness. Dissolution of stones may take several mo. Stone recurrence occurs in 30%–
50% of patients within 5 yr.

Dosis neonatal: 10 a 15 mg/kg/12 h, VO1.

1. Vento M, Moro M. De guardia en Neonatología. 2 ed. Editorial Ergon: España (Madrid) 2008.

Efectos adversos:

Náuseas, vómitos, flatulencia, estreñimiento y dolor abdominal.

Incompatibilidades: los antiácidos que contienen aluminio inhiben su absorción.